Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Alzheimer’s Markers Predict Start of Mental Decline

By LabMedica International staff writers
Posted on 30 May 2013
Biomarkers for Alzheimer’s disease have been identified that could potentially predict which patients will develop the disorder later in life.

The ability of molecular biomarkers for Alzheimer’s disease (AD), including amyloid imaging and cerebrospinal fluid (CSF) biomarkers to predict when cognitive impairment will occur among cognitively normal adults has been investigated. More...


Scientists at Washington University School of Medicine (St. Louis, MO, USA) studied and measured the levels of the biomarkers in a total of 201 individual volunteers aged 45 to 89 years who met all the inclusion criteria. On average, the data available on study participants spanned four years, with the longest recorded over 7.5 years. The CSF biomarkers included Ab42, tau, ptau181, tau/Ab42, ptau181/Ab42. Participants with amyloid imaging and CSF collection within one year of a clinical assessment indicating normal cognition were eligible.

Levels of Ab42, total tau, and ptau181 were measured using an enzyme-linked immunoassay, (ELISA) called INNOTEST (Innogenetics; Ghent, Belgium), which has a lowest detection limit of 60 pg/mL, and the standards range is 75–1,200 pg/mL. The scientists found that all of the markers were equally good at identifying subjects who were likely to develop cognitive problems and at predicting how soon they would become noticeably impaired. They then paired the biomarkers data with demographic information, testing to see if sex, age, race, education, and other factors could improve their predictions.

Abnormal levels of all biomarkers were associated with faster time to cognitive impairment, and some participants with abnormal biomarker levels remained cognitively normal for up to 6.6 years. No differences in predictive value were found between the individual biomarkers nor did they find differences between the expanded biomarker models. Each expanded model better predicted incident cognitive impairment than the model containing the biomarker alone.

Catherine Roe, PhD, research assistant professor of neurology, and lead author, said, “We wanted to see if one marker was better than the other in predicting which of our participants would get cognitive impairment and when they would get it. We found no differences in the accuracy of the biomarkers. We can better predict future cognitive impairment when we combine biomarkers with patient characteristics. Knowing how accurate biomarkers are is important if we are going to someday be able to treat Alzheimer’s before symptoms and slow or prevent the disease.” The study was published on April 10, 2013, in the journal Neurology.

Related Links:

Washington University School of Medicine
Innogenetics



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Urinalysis Solution
UN-9000
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.